Literature DB >> 26668645

Chronic nerve injury-induced Mas receptor expression in dorsal root ganglion neurons alleviates neuropathic pain.

Yuanting Zhao1, Yue Qin1, Tuanjiang Liu1, Dingjun Hao1.   

Abstract

Neuropathic pain, which is characterized by hyperalgesia, allodynia and spontaneous pain, is one of the most painful symptoms that can be experienced in the clinic. It often occurs as a result of injury to the peripheral nerves, dorsal root ganglion (DRG), spinal cord or brain. The renin-angiotensin system (RAS) plays an important role in nociception. As an essential component of the RAS, the angiotensin (Ang)-(1-7)/Mas axis may be involved in antinociception. The aim of the present study was to explore the expression pattern of Mas in DRG neurons following chronic nerve injury and examine the effects of Mas inhibition and activation on neuropathic pain in a chronic constriction injury (CCI) rat model. The results showed, that compared with the sham group, CCI caused a time-dependent induction of Mas expression at both the mRNA and the protein levels in DRG neurons. Consistent with the results, isolated DRG neurons showed a time-dependent increase in Ang-(1-7) binding on the cell membrane following the CCI surgery, but not the sham surgery. Compared with the sham control groups, CCI significantly decreased the paw withdrawal latency and threshold, and this was markedly improved and aggravated by intrathecal injection of the selective Mas agonist Ang-(1-7) and the selective Mas inhibitor D-Pro7-Ang-(1-7), respectively. In conclusion, this study has provided the first evidence, to the best of our knowledge, that the Mas expression in DRG neurons is time-dependently induced by chronic nerve injury and that the intrathecal activation and inhibition of Mas can improve and aggravate CCI-induced neuropathic pain, respectively. This study has provided novel insights into the pathophysiological process of neuropathic pain and suggests that the Ang-(1-7)/Mas axis could be an effective therapeutic target for neuropathic pain, warranting further study.

Entities:  

Keywords:  Mas receptor; angiotensin-(1–7); chronic constriction injury; dorsal root ganglion; neuropathic pain

Year:  2015        PMID: 26668645      PMCID: PMC4665121          DOI: 10.3892/etm.2015.2801

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  26 in total

Review 1.  Angiotensin-(1-7): an update.

Authors:  R A Santos; M J Campagnole-Santos; S P Andrade
Journal:  Regul Pept       Date:  2000-07-28

2.  Angiotensin-(1-7) induces peripheral antinociception through mas receptor activation in an opioid-independent pathway.

Authors:  Aline C O Costa; Lenice K Becker; Eder R Moraes; Thiago R L Romero; Luciana Guzzo; Robson A S Santos; Igor D G Duarte
Journal:  Pharmacology       Date:  2012-03-12       Impact factor: 2.547

3.  Angiotensin (1-7) induces MAS receptor internalization.

Authors:  Mariela M Gironacci; Hugo P Adamo; Gerardo Corradi; Robson A Santos; Pablo Ortiz; Oscar A Carretero
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

4.  A new role for the renin-angiotensin system in the rat periaqueductal gray matter: angiotensin receptor-mediated modulation of nociception.

Authors:  A Pelegrini-da-Silva; A R Martins; W A Prado
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

5.  Dorsal Root Ganglia Sensory Neuronal Cultures: a tool for drug discovery for peripheral neuropathies.

Authors:  Giorgia Melli; Ahmet Höke
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

6.  Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.

Authors:  Chad Vickers; Paul Hales; Virendar Kaushik; Larry Dick; James Gavin; Jin Tang; Kevin Godbout; Thomas Parsons; Elizabeth Baronas; Frank Hsieh; Susan Acton; Michael Patane; Andrew Nichols; Peter Tummino
Journal:  J Biol Chem       Date:  2002-01-28       Impact factor: 5.157

Review 7.  New therapy for neuropathic pain.

Authors:  Hirokazu Mizoguchi; Chizuko Watanabe; Akihiko Yonezawa; Shinobu Sakurada
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

Review 8.  ACE2: a new target for cardiovascular disease therapeutics.

Authors:  Mohan K Raizada; Anderson J Ferreira
Journal:  J Cardiovasc Pharmacol       Date:  2007-08       Impact factor: 3.105

9.  Expression and transport of Angiotensin II AT1 receptors in spinal cord, dorsal root ganglia and sciatic nerve of the rat.

Authors:  Jaroslav Pavel; Hui Tang; Stephen Brimijoin; Armen Moughamian; Tsuyoshi Nishioku; Julius Benicky; Juan M Saavedra
Journal:  Brain Res       Date:  2008-10-17       Impact factor: 3.252

10.  Angiotensin-(1-7)-mediated signaling in cardiomyocytes.

Authors:  Enéas R M Gomes; Robson A S Santos; Silvia Guatimosim
Journal:  Int J Hypertens       Date:  2012-03-04       Impact factor: 2.420

View more
  5 in total

Review 1.  Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22.

Authors:  Sadashiva S Karnik; Khuraijam Dhanachandra Singh; Kalyan Tirupula; Hamiyet Unal
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  The Angiotensin-(1-7)/Mas Axis Counteracts Angiotensin II-Dependent and -Independent Pro-inflammatory Signaling in Human Vascular Smooth Muscle Cells.

Authors:  Laura A Villalobos; Álvaro San Hipólito-Luengo; Mariella Ramos-González; Elena Cercas; Susana Vallejo; Alejandra Romero; Tania Romacho; Raffaele Carraro; Carlos F Sánchez-Ferrer; Concepción Peiró
Journal:  Front Pharmacol       Date:  2016-12-15       Impact factor: 5.810

Review 3.  Multiple Aspects of Inappropriate Action of Renin-Angiotensin, Vasopressin, and Oxytocin Systems in Neuropsychiatric and Neurodegenerative Diseases.

Authors:  Ewa Szczepanska-Sadowska; Agnieszka Wsol; Agnieszka Cudnoch-Jedrzejewska; Katarzyna Czarzasta; Tymoteusz Żera
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

4.  Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.

Authors:  Brittany L Forte; Lauren M Slosky; Hong Zhang; Moriah R Arnold; William D Staatz; Meredith Hay; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Pain       Date:  2016-12       Impact factor: 6.961

5.  Involvement of MrgprC in Electroacupuncture Analgesia for Attenuating CFA-Induced Thermal Hyperalgesia by Suppressing the TRPV1 Pathway.

Authors:  Ying-Jun Liu; Xiao-Xi Lin; Jian-Qiao Fang; Fang Fang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-12       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.